Assertio Therapeutics, Inc
assertiotx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2020 10-Q, filed May 11, 2020. Its latest SEC filing is a 25-NSE from Jun 16, 2026.
10-Q for Q1 FY2020, filed May 11, 2020
The sections below describe the company as of the FY2019 annual report.
What Did They Do?
Sells medicines for migraine and acute pain to wholesale distributors and specialty pharmacies.
10-K for FY2019, filed Mar 10, 2020CAMBIA is a non‑steroidal anti‑inflammatory drug (NSAID) indicated for the acute treatment of migraine attacks with or without aura in…View ↗
Zipsor is an NSAID indicated for relief of mild to moderate acute pain in adults. Zipsor uses proprietary ProSorb® delivery technology to…View ↗
We sell commercial products to wholesale distributors and specialty pharmacies. Product sales revenue is recognized when title has…View ↗
Who Were Their Customers?
The company sells its commercial medicines to wholesale distributors and specialty pharmacies; three large national wholesale distributors account for most of its business.
10-K for FY2019, filed Mar 10, 2020
10-K for FY2019, filed Mar 10, 2020
Consolidated Revenue Accounts Receivable related to product shipments 2019 2018 2017 2019 2018 2017 McKesson Corporation 16 % 14 % 36 % 46…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2020, filed May 11, 2020
$41.2MView ↗
- ▲ Now profitable
- vs −$14.3M in Q1 FY2019
-
May 22, 2020
Nasdaq listing transferred to a new holding company
The holding company assumed the ASRT listing, while Nasdaq sought to delist Assertio Therapeutics shares.
Sources
8-K, filed May 22, 2020
Following the consummation of the Assertio Reorganization, shares of Assertio Holdings Common Stock continue to trade on the Nasdaq Stock…View ↗
-
Apr 24, 2020
Nasdaq warned that Assertio could face delisting
Assertio had until December 28, 2020 to regain compliance.
Sources
8-K, filed Apr 24, 2020
In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of the Notice to…View ↗
-
Mar 17, 2020
Assertio agreed to merge with Zyla Life Sciences
The agreement would bring Zyla into the combined company, subject to stockholder approvals and other closing conditions.
Sources
8-K, filed Mar 17, 2020
On March 16, 2020, Assertio Therapeutics, Inc. a Delaware corporation (“Assertio”), entered into an Agreement and Plan of Merger (the…View ↗
Portfolio divestitures
The older report described a broader set of marketed medicines, including NUCYNTA, Gralise and Lazanda. The latest report describes CAMBIA and Zipsor as current products and says rights to Gralise and NUCYNTA were transferred to Alvogen and Collegium.
10-K for FY2016, filed Feb 24, 2017 10-K for FY2019, filed Mar 10, 2020Depomed is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. Our current specialty…View ↗
Gralise® (gabapentin), a once‑daily product for the management of postherpetic neuralgia (PHN), that we launched in October 2011.View ↗
Lazanda® (fentanyl) nasal spray, a product for the management of breakthrough cancer pain in cancer patients 18 years of age and older who…View ↗
Assertio Therapeutics, Inc. (Assertio or the Company) is a leading diversified, specialty pharmaceutical company focused on distinctive…View ↗
Gralise is a once‑daily formulation of gabapentin indicated for management of postherpetic neuralgia (PHN), a persistent pain condition…View ↗
In December 2017, we entered into the Commercialization Agreement with Collegium, which we amended in November 2018. Pursuant to the…View ↗
NUCYNTA commercialization
The older report described Assertio selling NUCYNTA products itself. The latest report describes Collegium taking over sales and marketing, with Assertio receiving royalties, before Assertio transferred its rights in the franchise.
10-K for FY2016, filed Feb 24, 2017 10-K for FY2019, filed Mar 10, 2020
Who Did They Compete With?
Competes with Pfizer, Arbor Pharmaceutical, Teva, and Daiichi-Sankyo
10-K for FY2019, filed Mar 10, 2020Gralise Gabapentin is currently sold by Pfizer Inc. (Pfizer) as Neurontin® and by several generic manufacturers for adjunctive therapy for…View ↗
Loading...
